Clinical Trial

Efficacy of Superoxide Dismutase Spray in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
This study was withdrawn prior to enrollment due to administrative error in the registration process, specifically an incorrect ethics approval number was recorded. A corrected version of the study has been re-registered under a new record.
Summary
Radiotherapy always results in many complications such as radiation dermatitis,dry mouth, cranial nerve damage, and swallowing function. Among them,radiation dermatitis is confirmed to occur in the majority of tumor patientsreceiving radiotherapy, which not only affects the appearance but also causesthe interruption of radiotherapy in severe cases. At present, there is no standard treatment for radiation dermatitis. Superoxide dismutase (SOD) Spray is able to removefree radicals produced during radiotherapy, which may provide a new way andmethod for the prevention and treatment of radiation dermatitis. In addition,the product has obtained a safety assessment report from a third-party testingorganization, proving that it has fully met the applied human body standards. This clinical trial studies the effect of superoxide dismutase (SOD) Spray in preventing radiationdermatitis in Head and Neck Cancer.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-06-24
notable Enrollment reduced: 140 -> 0 participants 2026-06-24
Trial Details
NCT Number NCT07400016
Lead Sponsor West China Hospital
Conditions Radiation Dermatitis
Start Date 2026-02-10
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23